Developer docs
API playgroundTry for free, no card

Search company profiles

Histogen

Full company profile

uuid0004wyg

Namestring
Histogen
Legal namestring
Histogen Inc.
Websiteurl
histogen.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Histogen Inc. was a publicly traded regenerative medicine company headquartered in San Diego, California, founded in 2007. The company operated on a 'novel biological platform that replaces and regenerates tissues in the body,' positioning itself to address unmet medical needs in tissue regeneration and repair across multiple medical conditions. Its core technology centered on regenerative therapeutics, with clinical development allocated to advancing therapies targeting tissue repair; however, no specific products, FDA approvals, or commercial launches are documented in the available data, indicating a clinical-stage profile that never reached meaningful commercialization.

The company's business model relied on capital markets rather than product revenue. It funded operations through a series of equity and preferred stock issuances — including $24.9M (2015), $6.0M (2016), $14.0M (2020), $6.5M (2021), $4.75M (2022), and $5.0M (2022) — supplemented by non-dilutive grants from the National Science Foundation and the U.S. Department of War. In May 2020, Histogen acquired Conatus Pharmaceuticals for an undisclosed amount, broadening its clinical pipeline. The company maintained a small footprint of 11-50 employees and never disclosed named customers, recurring revenue, or a go-to-market motion, consistent with pre-commercial biotech operations.

By early 2026, Histogen had entered the final phase of its wind-down process, with a court date scheduled for March to address asset recovery proceedings. The company was delisted from NASDAQ under ticker HSTO. Its listed leadership spanned President & CEO Richard Pascoe, Founder and Scientific Advisor Gail K. Naughton, Executive Chairman and Interim President & CEO Steven J. Mento, and SVP of Tech Ops Martin Latterich. Iterative small financings under deteriorating conditions and the absence of commercial revenue signal that the company was unable to advance its pipeline to a self-sustaining stage.

Short descriptiontext

Histogen Inc. was a San Diego-based, publicly traded regenerative medicine company developing a biological platform to replace and regenerate tissues in the body, targeting unmet needs in tissue repair before entering wind-down proceedings by 2026.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
regenerative medicine, tissue regeneration therapeutics, biologics platform, clinical-stage biotech, cell-based therapy
Industry3 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
Product category
Regenerative Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Operations, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Histogen is a regenerative medicine company developing a proprietary biological platform intended to replace and regenerate tissues in the body. The company focused on advancing regenerative therapeutics through clinical development and research, targeting unmet medical needs in tissue repair and regeneration.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Regenerative Therapeutics Platform
CategoryRegenerative Therapeutics
Description

Proprietary biological platform designed to replace and regenerate tissues in the body, targeting unmet medical needs in tissue repair and regeneration. Intended for healthcare providers and patients requiring regenerative treatments.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vericel develops autologous cell therapies for cartilage repair (MACI) and severe burns, directly overlapping with Histogen's HST-003 cartilage regeneration program and skin regeneration efforts. It is a relevant peer given Histogen's focus on musculoskeletal regenerative biologics.

TypeDirect peer
Description

Mesoblast develops allogeneic cell-based regenerative therapies (remestemcel-L, rexlemestrocel-L) targeting inflammatory and musculoskeletal conditions. Highly comparable as a publicly traded regenerative medicine company pursuing similar tissue repair indications.

3Athersys Inc.
TypeDirect peer
Description

Athersys developed MultiStem, a multipotent adult progenitor cell therapy for regenerative indications including stroke and ARDS. Comparable as a clinical-stage cell therapy peer that has similarly faced capital and clinical-development headwinds.

TypeDirect peer
Description

Capricor is developing allogeneic cardiosphere-derived cell therapies (CAP-1002) for Duchenne muscular dystrophy and other indications. Comparable as a small-cap clinical regenerative medicine company with similar financing patterns.

5Pluristem Therapeutics
TypeDirect peer
Description

Pluristem developed placenta-derived cell therapy products (PLX-PAD, PLX-R18) for regenerative indications including muscle injury and hematologic disorders. Comparable small-cap regenerative cell therapy peer with similar clinical-stage profile.

TypeDirect peer
Description

MiMedx develops and commercializes placental tissue allografts for wound care, surgical recovery, and regenerative applications. Comparable regenerative medicine peer with commercial products in adjacent tissue-repair indications.

TypeBroad incumbent
Description

Smith & Nephew acquired Osiris Therapeutics in 2019 and continues to develop and market regenerative wound care and orthobiologic products. Functions as a broad incumbent in the regenerative medicine space where Histogen operated.

8Caladrius Biosciences
TypeEmerging player
Description

Caladrius is developing CD34+ cell-based regenerative therapies for ischemic conditions. A small emerging regenerative medicine peer pursuing tissue-repair mechanisms similar to Histogen's platform approach.

TypeEmerging player
Description

InGeneron develops autologous regenerative cell therapies using adipose-derived stem cells for orthopedic and wound healing indications. Comparable niche regenerative cell therapy company targeting musculoskeletal applications like Histogen's HST-003.

10Fortify Biosciences
TypeEmerging player
Description

Fortify is a regenerative tissue engineering company developing bioengineered constructs for cartilage and other musculoskeletal repair. Comparable emerging peer in cartilage and musculoskeletal regeneration where Histogen's HST-003 was positioned.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Histogen

Regenerative Therapeuticshistogen.com

Histogen Inc. was a San Diego-based, publicly traded regenerative medicine company developing a biological platform to replace and regenerate tissues in the body, targeting unmet needs in tissue repair before entering wind-down proceedings by 2026.

What Histogen does

Histogen Inc. was a publicly traded regenerative medicine company headquartered in San Diego, California, founded in 2007. The company operated on a 'novel biological platform that replaces and regenerates tissues in the body,' positioning itself to address unmet medical needs in tissue regeneration and repair across multiple medical conditions. Its core technology centered on regenerative therapeutics, with clinical development allocated to advancing therapies targeting tissue repair; however, no specific products, FDA approvals, or commercial launches are documented in the available data, indicating a clinical-stage profile that never reached meaningful commercialization.

The company's business model relied on capital markets rather than product revenue. It funded operations through a series of equity and preferred stock issuances — including $24.9M (2015), $6.0M (2016), $14.0M (2020), $6.5M (2021), $4.75M (2022), and $5.0M (2022) — supplemented by non-dilutive grants from the National Science Foundation and the U.S. Department of War. In May 2020, Histogen acquired Conatus Pharmaceuticals for an undisclosed amount, broadening its clinical pipeline. The company maintained a small footprint of 11-50 employees and never disclosed named customers, recurring revenue, or a go-to-market motion, consistent with pre-commercial biotech operations.

By early 2026, Histogen had entered the final phase of its wind-down process, with a court date scheduled for March to address asset recovery proceedings. The company was delisted from NASDAQ under ticker HSTO. Its listed leadership spanned President & CEO Richard Pascoe, Founder and Scientific Advisor Gail K. Naughton, Executive Chairman and Interim President & CEO Steven J. Mento, and SVP of Tech Ops Martin Latterich. Iterative small financings under deteriorating conditions and the absence of commercial revenue signal that the company was unable to advance its pipeline to a self-sustaining stage.

Histogen firmographics

Firmographics
Name
Histogen
Legal name
Histogen Inc.
Website
https://histogen.com
Company type
Public
Founded year
2007
Operating status
Closed
Headcount range
11–50 employees
Short description
Histogen Inc. was a San Diego-based, publicly traded regenerative medicine company developing a biological platform to replace and regenerate tissues in the body, targeting unmet needs in tissue repair before entering wind-down proceedings by 2026.
Ownership category
akta.pro rank

Histogen industry classification

Industry
Product category
Regenerative Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Tissue regeneration therapeutics
  • Biologics platform
  • Clinical-stage biotech
  • Cell-based therapy

Where Histogen is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Histogen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel

Histogen product offering

Product offering

Core offering

Histogen is a regenerative medicine company developing a proprietary biological platform intended to replace and regenerate tissues in the body. The company focused on advancing regenerative therapeutics through clinical development and research, targeting unmet medical needs in tissue repair and regeneration.

Differentiator

Problem solved

Functional benefit

Products and services

  • Regenerative Therapeutics Platform Proprietary biological platform designed to replace and regenerate tissues in the body, targeting unmet medical needs in tissue repair and regeneration. Intended for healthcare providers and patients requiring regenerative treatments.

Companies that use Histogen

Customer profile

Segments1 record

Ideal customer profiles1 record

Histogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Histogen partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Histogen competitors and assessment

Company assessment

Direct peers

  • Vericel Corporation: Vericel develops autologous cell therapies for cartilage repair (MACI) and severe burns, directly overlapping with Histogen's HST-003 cartilage regeneration program and skin regeneration efforts. It is a relevant peer given Histogen's focus on musculoskeletal regenerative biologics.
  • Mesoblast Limited: Mesoblast develops allogeneic cell-based regenerative therapies (remestemcel-L, rexlemestrocel-L) targeting inflammatory and musculoskeletal conditions. Highly comparable as a publicly traded regenerative medicine company pursuing similar tissue repair indications.
  • Athersys Inc. Athersys developed MultiStem, a multipotent adult progenitor cell therapy for regenerative indications including stroke and ARDS. Comparable as a clinical-stage cell therapy peer that has similarly faced capital and clinical-development headwinds.
  • Capricor Therapeutics: Capricor is developing allogeneic cardiosphere-derived cell therapies (CAP-1002) for Duchenne muscular dystrophy and other indications. Comparable as a small-cap clinical regenerative medicine company with similar financing patterns.
  • Pluristem Therapeutics: Pluristem developed placenta-derived cell therapy products (PLX-PAD, PLX-R18) for regenerative indications including muscle injury and hematologic disorders. Comparable small-cap regenerative cell therapy peer with similar clinical-stage profile.
  • MiMedx Group: MiMedx develops and commercializes placental tissue allografts for wound care, surgical recovery, and regenerative applications. Comparable regenerative medicine peer with commercial products in adjacent tissue-repair indications.

Broad incumbents

  • Smith & Nephew (Osiris Therapeutics legacy): Smith & Nephew acquired Osiris Therapeutics in 2019 and continues to develop and market regenerative wound care and orthobiologic products. Functions as a broad incumbent in the regenerative medicine space where Histogen operated.

Emerging players

  • Caladrius Biosciences: Caladrius is developing CD34+ cell-based regenerative therapies for ischemic conditions. A small emerging regenerative medicine peer pursuing tissue-repair mechanisms similar to Histogen's platform approach.
  • InGeneron Inc. InGeneron develops autologous regenerative cell therapies using adipose-derived stem cells for orthopedic and wound healing indications. Comparable niche regenerative cell therapy company targeting musculoskeletal applications like Histogen's HST-003.
  • Fortify Biosciences: Fortify is a regenerative tissue engineering company developing bioengineered constructs for cartilage and other musculoskeletal repair. Comparable emerging peer in cartilage and musculoskeletal regeneration where Histogen's HST-003 was positioned.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Histogen social profiles

Digital presence

Histogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Histogen leadership team

Management profile

Number of profiles

Profiles4 records

Histogen funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Histogen M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Histogen

What does Histogen do?

Histogen is a regenerative medicine company developing a proprietary biological platform intended to replace and regenerate tissues in the body. The company focused on advancing regenerative therapeutics through clinical development and research, targeting unmet medical needs in tissue repair and regeneration.

Is Histogen a public or private company?

Histogen is a public company. It is classified as public and is currently closed.

When was Histogen founded?

Histogen was founded in 2007. It employs 11 to 50 people.

Where is Histogen based?

Histogen is headquartered in San Diego, United States, in the North America region.

Who are Histogen's main competitors?

Direct peers on record are Vericel Corporation, Mesoblast Limited, Athersys Inc., Capricor Therapeutics, Pluristem Therapeutics and MiMedx Group. Smith & Nephew (Osiris Therapeutics legacy) is listed as a broad incumbent. Emerging players are Caladrius Biosciences, InGeneron Inc. and Fortify Biosciences.

Does Histogen have an API?

No public API is recorded for Histogen.

What industry is Histogen in?

Histogen's product category is Regenerative Therapeutics. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device and Diagnostic industryHuman ECM for Devices and TherapeuticsThe article details the development and applications of a human extracellular matrix (hECM) material manufactured by Histogen Inc. using neonatal fibroblasts in a scalable bioreactor system to mimic embryonic tissue characteristics. This cell-free product offers an alternative to animal-derived or living cell-based therapies for medical devices, therapeutics, and research, addressing challenges like immune rejection and storage stability.GlobeNewswireHistogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share OfferingHistogen Inc. filed voluntary Chapter 11 petitions in the Southern District of California to confirm a plan of liquidation. The company intends to distribute all estate value to stakeholders, including shareholders, and is represented by DLA Piper and Armanino LLP.BioSpaceFresh Tracks, Histogen to Shutter Businesses in Absence of Viable OptionsFresh Tracks and Histogen announced dissolution and liquidation, with Fresh Tracks laying off most employees by early October 2023 and Histogen by end of September 2023. Both will discontinue clinical development programs, and Histogen may sell pipeline assets to stockholders. Shareholder approval is still pending for both.BenzingaMarkets Open Lower; US Housing Starts Fall In AugustU.S. stocks traded lower on Tuesday, with the Dow Jones falling around 40 points and the S&P 500 dropping 0.15%, while the NASDAQ fell 0.33%. Housing starts in the U.S. fell 11.3% month-over-month to an annualized rate of 1.283 million in August, recording the lowest level since June 2020, though building permits rose 6.9% to a 10-month high. Individual stocks saw significant movements, with Connexa Sports Technologies shares surging 130% and Avinger shares rising 66% following a product launch announcement, while Histogen shares dropped 45% after board approval of liquidation.BioWorldAmid hard industry times, Histogen gives up as thinner Kinnate hangs onHistogen Inc. adopted a shutdown plan distributing remaining cash to stockholders after winding down operations. Kinnate Biopharma Inc. laid off 70% of its workforce, including all employees at its Shanghai subsidiary, leaving 28 full-time employees.BenzingaShort Volatility Alert: Histogen IncOn Friday, shares of Histogen Inc (NASDAQ:HSTO) experienced volatile short activity, with the stock price surging +54.24% to $1.33. The securities lending volatility indicator from Tidal Markets, in partnership with Benzinga Insights, detected unusual short activity with a +110.37% volatility change, generating a 'Strong Sell' recommendation based on bearish signal trends. Securities lending volatility alerts are designed to serve as upstream indicators of potential downstream stock market movements.GlobeNewswireHistogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Histogen Inc. granted Alfred J. Spada, its newly appointed executive vice president and chief scientific officer, a nonqualified stock option to purchase 106,793 shares at $1.04. The grant was made as an inducement to his employment and approved under NASDAQ Listing Rule 5635(c)(4). The option vests over four years with a ten-year term.GlobeNewswireHistogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific OfficerHistogen Inc. appointed Alfred P. Spada as Executive Vice President and Chief Scientific Officer. Spada brings over 35 years of experience, including roles at Aya Biosciences and Conatus Pharmaceuticals. The hiring supports Histogen's clinical trial planning for emricasan to treat bacterial skin infections.GlobeNewswireHistogen to Report Second Quarter 2022 Financial Results and Provide Business UpdateHistogen Inc. will report its second-quarter 2022 financial results after market close on August 11, 2022. The company's pipeline includes HST-003 and HST-004 for joint and spinal disc repair, and emricasan, CTS-2090, and CTS-2096 for infectious and inflammatory diseases.